Eliyahou Et Al Harari Purchases 81,300 Shares of CapsoVision (NASDAQ:CV) Stock

CapsoVision, Inc. (NASDAQ:CV) major shareholder Eliyahou Et Al Harari acquired 81,300 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The shares were bought at an average cost of $6.09 per share, for a total transaction of $495,117.00. Following the acquisition, the insider directly owned 3,282,051 shares in the company, valued at $19,987,690.59. This represents a 2.54% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Eliyahou Et Al Harari also recently made the following trade(s):

• On Friday, June 26th, Eliyahou Et Al Harari bought 13,850 shares of CapsoVision stock. The shares were bought at an average cost of $7.35 per share, with a total value of $101,797.50.

CapsoVision Stock Up 3.8%

CV stock traded up $0.22 during mid-day trading on Friday, reaching $5.99. 87,049 shares of the company traded hands, compared to its average volume of 234,181. The company has a fifty day moving average price of $6.87 and a 200-day moving average price of $6.71. CapsoVision, Inc. has a 52-week low of $3.43 and a 52-week high of $15.37.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter. The firm had revenue of $2.79 million for the quarter.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Benchmark cut their price target on shares of CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating for the company in a report on Friday, March 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CapsoVision in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Millennium Management LLC bought a new stake in CapsoVision during the fourth quarter valued at approximately $163,000. State Street Corp grew its stake in CapsoVision by 340.7% in the 4th quarter. State Street Corp now owns 85,929 shares of the company’s stock worth $919,000 after buying an additional 66,429 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of CapsoVision by 34.1% in the 4th quarter. Geode Capital Management LLC now owns 154,264 shares of the company’s stock worth $1,649,000 after buying an additional 39,231 shares during the last quarter. Virtu Financial LLC bought a new position in shares of CapsoVision in the 4th quarter worth $128,000. Finally, Wells Fargo & Company MN raised its position in shares of CapsoVision by 66.4% during the 4th quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after buying an additional 2,508 shares in the last quarter.

About CapsoVision

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.